Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Noble Acquires Property with Significant Uranium, Rare Earth, Phosphorus & Silver Mineralization (click to learn more) V.AFM: Record Fy2024 & Q4 ‘24 Tin Production Fy2025 Production Guidance Exploration Success (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Gossamer Bio Inc GOSS

Healthcare Biotechnology
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH). Its product candidate Seralutinib, also known as GB002, is an investigational inhaled, small molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor... see more

Recent & Breaking News (NDAQ:GOSS)

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire 11 days ago

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire November 11, 2024

Gossamer Bio Announces Third Quarter 2024 Financial Results and Provides Business Update

Business Wire November 7, 2024

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire October 7, 2024

Gossamer Bio Announces Data Presentations at the European Respiratory Society Congress 2024

Business Wire August 26, 2024

Gossamer Bio Announces Second Quarter 2024 Financial Results and Provides Business Update

Business Wire August 12, 2024

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire June 7, 2024

Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference

Business Wire May 14, 2024

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire May 10, 2024

Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update

Business Wire May 7, 2024

Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications

Business Wire May 6, 2024

Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine

Business Wire May 3, 2024

Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors

Business Wire March 12, 2024

Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Business Wire March 5, 2024

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire January 8, 2024

Gossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023

Business Wire December 13, 2023

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire December 5, 2023

Gossamer Bio Appoints Bob Smith as Chief Commercial Officer

Business Wire December 5, 2023

Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors

Business Wire November 29, 2023

Gossamer Bio Announces Third Quarter 2023 Financial Results and Provides Business Update

Business Wire November 9, 2023